cxcl-10

Artemotil (SM-227) is a new, fast-acting antimalarial drug.

AMG 487 is a potent and selective antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively.

GW9508(GW 9508) is a potent and selective agonist for FFA1 (GPR40), stimulates insulin secretion in a glucose-sensitive manner.

NI-0801 (Anti-CXCL10 / IP-1) is a CHO-expressed humanized monoclonal antibody targeting CXCL10/IP-10 for the study of vitiligo and biliary cirrhosis.

NBI-74330 is a high-affinity CXCR3 antagonist that inhibits the binding of CXCR3 to its ligands CXCL10 and CXCL11, reduces the formation of atherosclerotic plaques in LDL receptor-deficient mice, and decreases the migration of CD4+ T cells and macrophages to the peritoneum.

Astin C (Asterin), a naturally occurring cyclic peptide that can be extracted from Aster tataricus, specifically blocks IRF3 recruitment at the STING signalosome inhibiting cGAS-STING signaling and innate inflammatory responses triggered by cytoplasmic dna, resulting in mice that are more susceptible to HSV-1 infection and significantly attenuating autoinflammatory responses.

STINGDegrader-2 (Compound SI-43) is an inhibitor and mutant-specific degrader of STING. It effectively suppresses cGAMP-induced STING activation and significantly reduces the release of IFN-β and CXCL-10. By binding to two pockets of the STING dimer, it inhibits activity and induces proteasome-independent degradation of the mutant STINGS154 and STINGM155 (DC50 values of 0.31 and 0.76 μM, respectively). STINGDegrader-2 is applicable in the study of STING-related autoimmune diseases.

STING agonist-24 (CF504), a non-nucleotide small-molecule STING agonist, activates STING, leading to increased phosphorylation of STING, TBK1, and IRF3. It elevates levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells, demonstrating activity against SARS-CoV series strains [1].

STING agonist-23 (CF505) is a non-nucleotide, small-molecule compound that stimulates STING, enhancing the phosphorylation of STING, TBK1, and IRF3. It elevates the production of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells and demonstrates efficacy against SARS-CoV strains [1].

STING agonist-23 (CF508), a non-nucleotide small-molecule STING agonist, activates STING, thereby enhancing the phosphorylation of STING, TBK1, and IRF3. This activation elevates the production of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. Moreover, STING agonist-23 demonstrates efficacy against SARS-CoV series strains [1].

STING agonist-23 (CF510) is a non-nucleotide, small-molecule activator of the STING pathway. It initiates the phosphorylation of STING, TBK1, and IRF3, enhancing the production of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. Notably, it demonstrates activity against SARS-CoV series strains [1].